Aspirin Treatment Reduces Platelet Resistance to Deformation

Steven M. Bunn, Clark M. Smith II, Gundu H. R. Rao, and James G. White

The present investigation has evaluated the influence of aspirin, its constituents, and other nonsteroidal anti-inflammatory agents on the resistance of human platelets to aspiration into micropipettes. Aspirin increased the length of platelet extensions into the micropipette over the entire negative tension range of 0.04 to 0.40 dynes/cm after exposure to the drug in vitro or after ingestion of the agent. Other cyclooxygenase inhibitors, ibuprofen and indomethacin, did not increase platelet deformability. The influence of aspirin was mimicked to some degree by high concentrations of salicylic acid, but acetylation of platelets with acetic anhydride had little influence on platelet deformability. Incubation of platelets with both salicylic acid and acetic anhydride had no more effect than salicylic acid alone. Benzoic acid, chemically similar to salicylic acid, had a minimal effect. The studies demonstrate that aspirin makes platelets more deformable, while components of the drug or other nonsteroidal anti-inflammatory agents and cyclooxygenase inhibitors do not have the same influence on resistance to deformation. (Arteriosclerosis 7:385–388, July/August 1987)

Recent studies in our laboratory have used the technique of micropipette elastimetry to evaluate the resistance of platelets to deformation.1,2 Investigations into the effects of chilling and of antimotic agents demonstrated that intact microtubule coils are critical for platelet resistance to aspiration into micropipettes.1,2 Exposure of platelets to cytochalasin B before aspiration showed that actin microfilament assembly was also important in platelet stability.1 Exposure of platelets to aggregating agents dramatically altered platelet deformability. Thrombin, ADP, and the ionophore, A23187, stimulated platelet shape change and internal transformation associated with constriction of circumferential microtubule coils.3,4 Agonist-activated platelets were significantly softer than resting platelets on aspiration.5

Aspirin inhibits platelet cyclooxygenase, blocks thromboxane generation and prevents platelet secretion caused by potent agonists but does not affect shape change.6–13 It seemed reasonable, therefore, to determine whether or not aspirin would also block the influence of aggregating agents on deformability. We found that aspirin itself caused significant softening of resting platelets. Further studies revealed that other cyclooxygenase inhibitors did not affect platelet deformability, and the effect of aspirin was not fully reproduced by components of the drug.

Methods

Materials

Acetylsalicylic acid (ASA), salicylic acid, benzoic acid, and indomethacin were obtained from Sigma Chemical Company (St. Louis, Missouri). Acetic anhydride was obtained from Upjohn Company (Kalamazoo, Michigan). All the agents were suspended in Ca++/Mg++-free Hanks' Balanced Salt Solution (HBSS) to a final stock concentration of 10 mmol/L. All of the drugs were added to platelet suspensions at a final concentration of 100 μM/L and were incubated for 30 minutes at room temperature before the deformability studies were done. Salicylic acid was also incubated with platelets at a concentration of 200 μM/L.

Platelet Preparation

Blood was collected by venipuncture from healthy adult human donors after informed consent was obtained in accordance with the committee on human subjects at the University of Minnesota. Blood samples were obtained from volunteers who had taken no medications for 2 weeks prior to venipuncture or had ingested 650 mg of aspirin 2 hours earlier. The blood samples were immediately mixed with 3.8% trisodium citrate or citrate-citric acid, pH 6.5 (93 mmol/L sodium citrate, 70 mmol/L citric acid, and 140 mmol/L dextrose) in a ratio of nine parts blood to one part anticoagulant.14,15 Platelet-rich plasma (PRP) was separated from whole blood by centrifugation at 100 g for 15 minutes. Samples of PRP were mixed with an equal volume of the citrate-citric acid anticoagulant; then one volume of PRP mixture was added to nine volumes of Ca++/Mg++-free HBSS containing adenosine 5 mmol/L, theophylline 3 mmol/L, and human serum albumin 0.1%. The diluted platelets were incubated in this mixture for 15
Untreated

ASA

Salicylic acid

Acetic anhydride

Figure 1. Effects of aspirin, ibuprofen, and indomethacin on the stress response of normal platelets. The lines represent the computerized linear regression of the tension-extension data with correlation coefficients \( R^2 \geq 0.90 \).

Figure 2. Effects of aspirin, salicylic acid, and acetic anhydride on the stress response of normal platelets. The lines represent the computerized linear regression of the tension-extension length data with correlation coefficients \( R^2 \geq 0.90 \).

that was used to evaluate treated cells. Minor differences in pipette internal diameter were also accounted for in the data analysis as described below.

The changes in extension lengths were measured with a Hi-pad Digitizer (Bausch & Lomb, Houston, Texas) interfaced with a Terak 8510 Graphic Computer (Terak Corporation, Scottsdale, Arizona). A dimensionless extension parameter \( X \) was obtained by dividing the extension length in micrometers by the radius of the pipette \( R_p \) also in micrometers. A tension stress parameter \( P \times R_p \) was defined by multiplying the aspiration pressure \( P \) by the pipette radius. The stress response of the platelet was characterized by four quantifiable parameters. The cell extension length aspirated at the lowest tension was termed \( X_i \). The maximum extension length aspirated from the cell was referred to as \( X_m \) and the tension at which \( X_m \) was reached was designated \( T_m \). The slope of the linear portion of the stress response was also determined by linear regression analysis.

**Table 1. Initial Cell Extension, Slope, Maximum Extension Length, and Tension at Maximum Extension Length of Untreated and Treated Platelets**

<table>
<thead>
<tr>
<th>Platelet treatment</th>
<th>( X_i ) ( \pm ) SD</th>
<th>Slope</th>
<th>( X_m ) ( \pm ) SD</th>
<th>( T_m ) ( \pm ) SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated</td>
<td>1.15 ( \pm ) 0.13</td>
<td>12.71 ( \pm ) 0.65</td>
<td>4.30 ( \pm ) 0.30</td>
<td>0.280 ( \pm ) 0.03</td>
</tr>
<tr>
<td>Aspirin</td>
<td>2.72 ( \pm ) 0.25*</td>
<td>29.27 ( \pm ) 1.68*</td>
<td>8.32 ( \pm ) 0.61*</td>
<td>0.180 ( \pm ) 0.02*</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>1.18 ( \pm ) 0.15</td>
<td>9.97 ( \pm ) 0.56†</td>
<td>4.51 ( \pm ) 0.32</td>
<td>0.390 ( \pm ) 0.04*</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>1.42 ( \pm ) 0.24</td>
<td>13.64 ( \pm ) 0.64</td>
<td>4.98 ( \pm ) 0.64</td>
<td>0.317 ( \pm ) 0.03</td>
</tr>
</tbody>
</table>

The results within each experimental category were based on 40 to 50 cells. Values are mean \( \pm \) SD.

*Statistically different from untreated, \( p < 0.001 \).
†Statistically different from untreated, \( p < 0.01 \).
\( X_i \) = initial cell extension; \( X_m \) = maximum extension length; \( T_m \) = tension at maximum extension length.
ences between individual linear regressions was determined by fitting the data to four separate discriminant models. These were intercept and slope different, different intercept but same slope, same intercept but different slope, and same intercept and slope. The resulting sum of squares, residuals, F ratio, and coefficient of determination (R²) were used to assess the validity of the models, and p values were determined from the ratio.

Results

Treatment of platelets with ASA in vitro increased the deformability of the cells upon micropipette aspiration as seen in Figure 1 and Table 1. ASA increased the length of cell extensions into the micropipette with a doubling of initial (X₀) and maximum (Xₘ) extension lengths, and also significantly reduced the tension at which maximum extension was achieved. ASA treatment was not associated with any alteration of cell shape that could be visualized through the videomicroscope that was used during the micropipette aspirations. The effect of ASA on the mechanical properties of platelets was also observed after oral ingestion of the drug by healthy human volunteers. Platelets withdrawn by venipuncture 2 hours after ingestion of a 650 mg tablet of ASA manifested increased deformability more like treatment with salicylic acid rather than reproducing the effect of exposure to ASA (see Table 2). Unlike isolated salicylic acid or ASA treatment, the Tₘ of the dually exposed platelets was not decreased. Tₘ was unchanged if the platelets were treated with acetic anhydride first, but was somewhat increased after initial treatment with salicylic acid followed by acetic anhydride.

Discussion

ASA caused platelets to become soft after exposure to the drug in vitro and after oral ingestion. The agent increased the length of cell extensions into the micropipette over the entire range of negative tensions, and lowered the tension required for maximum cell deformation. Previous platelet aspiration studies emphasized the importance of an unencumbered surface for extension into the pipette. The state of assembly of the circumferential microtubule and its location in the resting, compared to activated, platelets were found to be major factors determining the availability of platelet surface for deformation. ASA had no effect on cell shape or location of the circumferential microtubule and yet increased the length of cell extensions drawn into the pipette at all tensions.

ASA reduced the minimum tension required to reach maximum cell deformation. Previous manipulations that increased platelet extensibility and maximum cell deformation had not shown this effect. Neither exposure to cold nor treatment with agonists decreased the tension at which maximum cell deformation was first achieved. Although the previous manipulations may have increased platelet

<table>
<thead>
<tr>
<th>Platelet treatment</th>
<th>X₀ ± SD</th>
<th>Slope</th>
<th>Xₘ ± SD</th>
<th>Tₘ ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated</td>
<td>1.15 ± 0.13</td>
<td>12.71 ± 0.65</td>
<td>4.30 ± 0.30</td>
<td>0.280 ± 0.03</td>
</tr>
<tr>
<td>Aspirin</td>
<td>2.72 ± 0.25*</td>
<td>29.27 ± 1.88*</td>
<td>8.32 ± 0.61*</td>
<td>0.180 ± 0.02*</td>
</tr>
<tr>
<td>Salicylic acid</td>
<td>2.00 ± 0.24*</td>
<td>20.78 ± 1.35*</td>
<td>5.63 ± 0.81*</td>
<td>0.205 ± 0.02*</td>
</tr>
<tr>
<td>Acetic anhydride</td>
<td>0.98 ± 0.25</td>
<td>11.20 ± 1.02</td>
<td>4.00 ± 0.19</td>
<td>0.334 ± 0.02*</td>
</tr>
<tr>
<td>Salicylic acid and acetic anhydride</td>
<td>1.89 ± 0.46†</td>
<td>20.08 ± 1.47*</td>
<td>5.85 ± 0.62†</td>
<td>0.245 ± 0.03</td>
</tr>
<tr>
<td>Acetic anhydride and salicylic acid</td>
<td>2.15 ± 0.36*</td>
<td>22.51 ± 1.77*</td>
<td>5.43 ± 0.70†</td>
<td>0.302 ± 0.02</td>
</tr>
</tbody>
</table>

Results within each experimental category were based on 40 to 50 cells. Values are mean ± SD.

*Statistically different from untreated, p < 0.001.
†Statistically different from untreated, p < 0.01.

X₀ = cell extension; Xₘ = maximum extension length; Tₘ = tension at maximum extension length.

Table 2. Deformability Parameters of Untreated and Treated Platelets
extensibility primarily by increasing the availability of the surface for deformation, ASA profoundly affected platelet deformability through a decrease in cell elasticity.

Aspirin, a well-known inhibitor of platelet cyclooxygenase, blocks the conversion of arachidonic acid to thromboxane A₂. Hence, agonist-induced secretion of granule contents and irreversible aggregation are prevented without affecting platelet shape change. Aspirin hydrolyzes to acetate and salicylic acid in plasma and tissues so that platelet cyclooxygenase is irreversibly inhibited by ASA-induced acetylation. On the other hand, salicylic acid does not suppress cyclooxygenase activity.

The increase in platelet deformability caused by ASA was not due to blockade of prostaglandin metabolism. Unlike ASA, other inhibitors of cyclooxygenase, such as ibuprofen and indomethacin, had little effect on platelet deformability. Ibuprofen tended to increase resistance to deformation as exemplified by an increase in the tension needed for maximum deformation. Indomethacin had no discernible effect.

The influence of ASA on platelet deformability was reproduced to some extent by the salicylic acid moiety of the compound. Salicylic acid significantly altered all of the deformability parameters in the same manner as ASA, although to a lesser degree. Doubling the concentration of salicylic acid did not increase platelet deformability more than the lower concentration of the drug. Acetylation of platelets with acetic anhydride had no influence on the initial or maximum cell extensions, and, contrary to ASA or salicylic acid, tended to increase the tension needed for maximum cell deformation. Benzoic acid, having a ring structure similar to that found in ASA and salicylic acid, had little influence on platelet deformability.

The effect of ASA did not appear to be due to a synergistic effect of acetylation and salicylic acid. Sequential incubation of platelets with acetic anhydride and salicylic acid did not increase platelet deformability more than exposure to salicylic acid alone. The potency of ASA in altering platelet deformability infers some specificity to the effect not shared by individual or combined treatment with more simple congeners of the drug.

The reduced resistance to deformation accompanying ASA treatment may counteract inhibitory actions of the drug on platelet reactivity. Increased deformability may mechanically augment platelet interaction with surfaces by facilitating the ease with which multiple point contacts are formed for firm attachment. Our group and others have reported augmented surface contact and spreading of ASA-treated platelets to vascular subendothelium under flow conditions compatible with the altered mechanical properties of the cell. The softening effect of ASA on platelets may be another factor contributing to the variable efficacy of the drug in preventing thrombosis in clinical trials.

References


Index Terms: platelet • deformability • aspirin
Aspirin treatment reduces platelet resistance to deformation.
S M Burris, C M Smith, 2nd, G H Rao and J G White

Arterioscler Thromb Vasc Biol. 1987;7:385-388
doi: 10.1161/01.ATV.7.4.385
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1987 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/7/4/385

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/